At EvON Medics, we aim to defeat devastating neurological diseases by engineering state-of-the-art medical devices equipped with extraordinary healthcare technologies. Our motto is clear - to enrich the quality of everyone’s lives through their mental well-being.
At EvON Medics, we aim to defeat devastating neurological diseases by engineering state-of-the-art medical devices equipped with extraordinary healthcare technologies. Our motto is clear - to enrich the quality of everyone’s lives through their mental well-being.
EvON Medics is the developer of the unique and patented olfactory treatment delivery systems (OTDS), invented by the Co-Founder, Dr. Evaristus Nwulia. OTDS is an advanced device that delivers nerve enriching and protective compounds, including botanical extracts into the olfactory regions of the brain. This application has also been refined for intensive stimulation of selective brain regions that serve important functions, such as emotion control, regulation of drives and cognitive appraisal. One of the products derived from the OTDS paradigm is the computerized olfactory training program (COT). COT is currently being applied for repairs of damaged brain circuits in Alzheimer’s Disease and brain trauma. In basic studies, COT regrows new brain cells and protects the brain from damages caused by infections, toxins, and other adverse environmental factors. We are also testing other applications of OTDS for treatment of drug addiction, chronic pain and depression that is refractory to medication management. Our application for management of drug addiction – computer-based orbitofrontal training (CBOT) – targets the hard-to-reach prefrontal brain region, a part of the brain that helps with regulation of drives and emotions. EvON Medics also develops diagnostic solutions for Alzheimer’s Disease and concussions as well as digital therapeutics for Remote Patient Monitoring (RPM) and remote management of neurological diseases.
Evaristus Nwulia, MD, Co-Founder of EvON Medics, LLC is a Johns Hopkins University-trained physician and neuroscientist known for pioneering translational work in olfactory neuroscience. In 2012, Dr. Nwulia developed a novel approach, apparatus, and kit for slowing neurodegenerative changes and memory decline in Alzheimer’s Disease. In April 2013, Dr. Nwulia partnered with Seun Falade, MD, a physician and public health specialist at Johns Hopkins to co-found EvON Medics, LLC in Elkridge, Maryland for the purpose of refinement of this Alzheimer’s treatment for commercialization.
Over the years, research and development at EvON Medics, LLC has led to the development of brain stimulation device prototypes and new drug ligands for treatment of numerous neuropsychiatric conditions, including traumatic brain injury, post-traumatic stress disorders, treatment resistant depression, obsessive-compulsive disorders, chronic pain, opioid addiction and dementias.
Since 2018, EvON Medics has been successful in raising over $14 million in non-dilutive funding through the Small Business Innovation Research (SBIR) Program from various institutes of the National Institutes of Health (NIH), including the National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) to fund its Clinical Trials and R&D.
EvON Medics, LLC received a non-dilutive grant of $2.9 million for its FAST-TRACK SBIR (Small Business Innovation Research) study
September 2022
For the development and evaluation of its Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P). This award is funded through the NIH HEAL (Helping to End Addiction Long-term) initiative and sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).
EvON Medics, LLC Co-Founder Appointed Director/Principal Investigator NeuroTech Harbor Technology Accelerator
September 2022
National Institute on Drug Abuse issues $2.8m SBIR Fast-track financial award to EvON Medics
May 2022
On May 9, 2022, the National Institute on Drug Abuse apart of the National Institutes of Health issued Small Business Innovation Research (SBIR) Fasttrack award of $2.8m to EvON Medics for the Development and Evaluation of its mobile health platform for remote management of substance use disorders (SUD). This study will address the healthcare needs of communities of socially disadvantaged populations that lag in the adoption of mobile platforms due to the inability to read, digital illiteracy, lack of access to smartphones, absence of reliable Wi-Fi or internet, and financial constraints.
George C. McFarland, MSW Joins EvON Medics as Advisor
June 01, 2021
Mr. George McFarland joins the EvON Medics Advisory Board effective June 1, 2021. George brings his wealth of experience managing over $100 million in grants and contracts to promote health and human development. His network and experience working with numerous organizations throughout the United States to improve the quality of life in communities affected by health and socially determined risks would also be valuable to EvON Medics as we continue to engage these underserved populations in our clinical trials.
Manuscript Publication: Comparative Effects of Repetitive Odor Identification and Odor Memory Tasks on Olfactory Engagement in Older Populations – A Pilot fMRI Study
April 30, 2020
On April 30, 2021, study results on the comparative effects of repetitive odor identification and odor memory tasks on olfactory engagement in older populations was published in the Dovepress Journal. This study evaluated human Blood Oxygen Level-Dependent (BOLD) responses in primary and higher-order olfactory regions of older adults, using odor memory and odor identification tasks. The goal was to determine which olfactory and memory regions of interest are more strongly engaged in older populations by comparing these two odor training tasks.
View link for more details.
National Institute on Aging issues $2.5m SBIR Phase II Financial Award to EvON Medics
April 29, 2021
National Institute on Drug Abuse issues $1.7m SBIR Phase II Financial Award to Evon Medics
September 2020
On September 23, 2020, the National Institute on Drug Abuse a part of the National Institutes of Health issued Small Business Innovation Research (SBIR) Phase II award of $1.7m to EvON Medics for the Development and Evaluation of its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for the treatment of Opioid Use Disorder. This is following a hugely successful SBIR Phase I study.
EvON Medics completes successful Phase I clinical trials
Mar, 2020
National Institute on Aging Issues SBIR Financial Award to EvON Medics
Oct 26, 2020We are pioneering natural solutions for longer and healthier lives with medical research, therapeutics, and devices.
Meet our team that brings a wealth of experience in science and technology.
We're helping millions to bring impact with purpose for the treatment of chronic neurodegenerative diseases
We have been working with some Fortune 500 clients
EvON Medics team will contact you within 3 business days after receiving an inquiry.
